Mika K. Derynck

CIK: 0001865125

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (14.3%)

Position reduction

Option Exercises (M)4 (57.1%)

Derivative conversions

Awards (A)2 (28.6%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

ELVN

Enliven Therapeutics, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (7 total)

ELVN
Enliven Therapeutics, Inc.
Aug 4, 2026
Exercise(M)
Direct
20.5K shares at avg. $22.47$460K
ELVN
Enliven Therapeutics, Inc.
Aug 4, 2026
Exercise(M)
Direct
27.6K shares at avg. $25.28$697K
ELVN
Enliven Therapeutics, Inc.
Aug 4, 2026
Exercise(M)
Direct
23.4K shares at avg. $14.85$347K
ELVN
Enliven Therapeutics, Inc.
Aug 4, 2026
Exercise(M)
Direct
87.4K shares at avg. $2.48$217K
ELVN
Enliven Therapeutics, Inc.
Aug 4, 2026
Sale(S)
Direct
158.8K shares at avg. $60.21$9.6M
ELVN
Enliven Therapeutics, Inc.
Feb 12, 2026
Award(A)
Stock Option (right to buy)
Direct
17.1K shares-
ELVN
Enliven Therapeutics, Inc.
Feb 6, 2025
Award(A)
Stock Option (right to buy)
Direct
20.5K shares-

		Type	Shares	Price		Ownership
Aug 4, 2026	ELVN Enliven Therapeutics, Inc.	Exercise(M)	20,491	$22.47	$460,433	Direct
Aug 4, 2026	ELVN Enliven Therapeutics, Inc.	Exercise(M)	27,567	$25.28	$696,894	Direct
Aug 4, 2026	ELVN Enliven Therapeutics, Inc.	Exercise(M)	23,364	$14.85	$346,955	Direct
Aug 4, 2026	ELVN Enliven Therapeutics, Inc.	Exercise(M)	87,373	$2.48	$216,685	Direct
Aug 4, 2026	ELVN Enliven Therapeutics, Inc.	Sale(S)	158,795	$60.21	$9,561,587	Direct
Feb 12, 2026	ELVN Enliven Therapeutics, Inc.	Award(A) Stock Option (right to buy)	17,126	-	-	Direct
Feb 6, 2025	ELVN Enliven Therapeutics, Inc.	Award(A) Stock Option (right to buy)	20,491	-	-	Direct

1-7 of 7 transactions

About Derynck Mika K

Derynck Mika K (SEC CIK 0001865125) files insider reports with the SEC as Director of Enliven Therapeutics, Inc. (ELVN).

Signal8 holds 3 ownership filings by Derynck Mika K, all Form 4s, filed between Feb 10, 2025 and Aug 6, 2026. Those filings report 7 transactions, from Feb 6, 2025 to Aug 4, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Derynck Mika K's filings is in BURLINGAME, CA.

Recent filings by Derynck Mika K

Aug 4, 2026: Option exercises of ELVN shares (4 lines, Form 4, code M).
Aug 4, 2026: Open-market sale of ELVN shares (Form 4, code S).
Feb 12, 2026: Grant or award of ELVN derivative securities (Form 4, code A).
Feb 6, 2025: Grant or award of ELVN derivative securities (Form 4, code A).

Other insiders filing for Enliven Therapeutics, Inc. (ELVN)

Kunkel Lori Anne, Officer
Hohl Benjamin, CHIEF FINANCIAL OFFICER
Collins Helen Louise, CHIEF MEDICAL OFFICER
BALL KRISTINE M, Director
Garland J. Scott, Director
ORBIMED ADVISORS LLC, 10% Owner

How to read Form 4 transaction codes